Category: Health Science
-
Biotech: Who will survive when the Covid-19 Hype Ends? Part II
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against Covid-19 (don’t look south of the border). Thanks to all citizens still wearing hats to hide their botched home-haircuts, and our essential workers who literally put their lives on the…
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Roadman Investments (LITT.V) really doesn’t want to talk about cedar leaf oil anymore
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions…
-
Leaping Forward: PredictMedix (PMED.C) partners with TechMahindra
Keynes once said that “the market can remain irrational longer than you can remain solvent”. Fundamentals departed market valuation long ago, but you could’ve at least expected market reaction to be in response to COVID-19 related news. Except it seems like that’s no longer the case.
-
![Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil]()
Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and…
-
Shroom Digest: Mushroom moves from MindMed, Yield Growth, New Wave, Yukoterre, Silo, EGF Theramed
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush.
-
Xphyto (XPHY.C) just unlocked a pipeline of biosensor screening projects
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly.
-
Predictmedix (PMED.C) inks deal to acquire a Telehealth company
Predictmedix and MobileWellbeing are attacking the Telehealth problem from different angles.
-
![Xphyto (XPHY.C) advances delivery system for Parkinson’s drug]()
Xphyto (XPHY.C) advances delivery system for Parkinson’s drug
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies.
-
I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three…
